Article Versions Notes

Shah NR, Bulitta JB, Kinzig M, Landersdorfer CB, Jiao Y, Sutaria DS, Tao X, Höhl R, Holzgrabe U, Kees F, et al. Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding. Pharmaceutics. 2019; 11(6):286. https://doi.org/10.3390/pharmaceutics11060286

Shah, Nirav R., Jürgen B. Bulitta, Martina Kinzig, Cornelia B. Landersdorfer, Yuanyuan Jiao, Dhruvitkumar S. Sutaria, Xun Tao, Rainer Höhl, Ulrike Holzgrabe, Frieder Kees, and et al. 2019. "Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding" Pharmaceutics 11, no. 6: 286. https://doi.org/10.3390/pharmaceutics11060286

Shah, N. R., Bulitta, J. B., Kinzig, M., Landersdorfer, C. B., Jiao, Y., Sutaria, D. S., Tao, X., Höhl, R., Holzgrabe, U., Kees, F., Stephan, U., & Sörgel, F. (2019). Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding. Pharmaceutics, 11(6), 286. https://doi.org/10.3390/pharmaceutics11060286